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regions and influences the volume effect.
Conclusions: A mechanistic model of normal-tissue damage is an effective
framework for summarising the radiobiological knowledgebase of radiation
pneumonitis, and plausible parameter values have been derived. Future pre-
dictive mechanistic modelling would require more quantitative histopathologi-
cal studies on relevant local dose effects, thereby providing stronger evidence
for the local dose-response relationship. This would provide a stepping stone
from which the mechanisms of organ function loss, as a result of 3D distribu-
tions of FSU inactivation, could be studied separately.
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Purpose: To estimate and compare the shortening of life expectancy (LE)
due to radiation-induced secondary cancers (SC) and cardiac events after
photon or proton radiotherapy (RT). Estimating the Life Years Lost (LYL) for
competing causes of treatment-related mortality allows direct long-term risk
comparison between alternative radiotherapy plans or modalities.
Materials: The largest clinical data sets available are used to extract dose-
response (DR) parameters for the excess relative risk (ERR) for each end-
point. The ERR is combined with the age- and gender-specific incidence in
the general population (GP) to estimate the absolute excess risk (AER). The
excess mortality rate (EMR) is then estimated by including the prognosis for
each endpoint. The remaining LE for a person of a specific age in the GP
gives the LYL for a patient dying at that age. Competing risks of death prior
to a treatment-related event is taken into account from life tables of child-
hood cancer survivors. Integrating over all ages gives the LYL attributable to
each complication. The LYL measure is sensitive to the associated mortality
and age dependency of late complications, weighting early occurring events
higher due to more years lost at younger ages. We apply the LYL measure
for comparing treatment plans created with 3D conformal RT (3D CRT), arc
therapy (RapidArc® (RA)) and spot-scanned intensity-modulated proton ther-
apy (IMPT) for craniospinal irradiation (CSI) of 10 paediatric patients.A paired
Monte Carlo method is used to test for difference in LYL between modalities.
The main source of uncertainty lies in the DR relationship for the different
endpoints. Samples are drawn from a log-transformed normal distribution
matching the confidence intervals (CI) of the DR parameters. For each sam-
ple, the difference in LYL between pairs of modalities was calculated and the
corresponding mean and CI for each patient was extracted from the distribu-
tion.
Results: Figure 1 shows the final LYL estimate averaged for all ten patients.
The attributable LYL varies among endpoints as a function of treatment tech-
nique. The dominating causes of LYL appear to be secondary lung cancer
and cardiac events as a result of the poor prognosis after these events. In
the paired samples test the total LYL was significantly lower for RA than for
3DCRT, mainly due to substantially lower cardiac dose, and LYL with IMPT
was significantly lower than for both photon techniques.
Figure 1. Estimated LYL attributable to various endpoints for the 3D-CRT, RA
and IMPT techniques. LYL varies between treatment techniques due to differ-
ences in the distribution of non-target dose. The full bars represent the mean
total LYL for the ten patients for each of the three techniques. Statistically
significant p-values from the paired comparison of LYL between techniques
show that these differences are relatively insensitive to uncertainty in DR pa-
rameters.
Conclusions: The LYL measure provides a framework for direct comparison
of SC risks and risks of other adverse late complications and is readily ap-
plicable to other treatment techniques and endpoints provided the necessary
model parameters are available. For the ten paediatric patients studied, we
found a significant difference in LYL favoring proton over photon radiotherapy.
We also found a difference favoring RA over 3DCRT, this ranking will however
depend strongly on the relative weight of SC and cardiac events.
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Purpose: Quality assurance (QA) in multi-centre clinical trials is essential to
ensure treatment is safely and effectively delivered. As QA requirements have
increased in complexity in parallel with evolution of radiotherapy (RT) delivery
techniques, a pressing need to facilitate digital data exchange and timely re-
view has emerged. Our objective is to present the platform developed for the
integration and standardization of QART activities within our pan-European
academic clinical trial organization.
Materials: Based on 30 years of RT clinical trial and QA experience, the cen-
tral coordinating team and QART strategic committee identified the essential
requirements for the platform: secure and easy access to data without on-
site hardware installation; integration within the coordinating centre’s existing
clinical remote data capture system; and the ability to both customize the plat-
form to specific studies and adapt to currently unforeseen future needs. After
retrospective testing within several clinical trials, the platform was introduced
in phases to participating sites and QART study reviewers.
Results: The resulting QA platform, integrating RT analysis software installed
at the coordinating centre, permits timely, secure, and fully digital central
DICOM-RT based data review (Figure 1). Participating sites submit requested
data through a standard secure upload webpage. Supplemental information
is submitted in parallel through web-based forms such as type of treatment
planning system and description of the treatment verification protocol. An
internal quality check by the coordinating team verifies data consistency, for-
matting, completeness, and anonymization. Personnel responsible for QART
reviews have remote online access to DICOM-RT data through a terminal
server, and receive relevant clinical data as well. Reviewers evaluate sub-
missions for protocol compliance through a standardized online evaluation
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matrix. Comments are collected by the coordinating centre after which par-
ticipating institutions are informed of the results.
Conclusions: This integrated, web-based central review platform facilitates
the performance of rapid, extensive, and prospective QART patient review
within large multinational clinical trials. Timely central review completed in
this manner allows reduction of the risk that trial outcomes are compromised
through inadequate radiation delivery.
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Purpose: In 2006, 937 new cases of cancer in larynx, pharynx and cavum
oris were registered in Denmark. Because the disease has often spread to
the lymph nodes, the patient is normally treated with radiotherapy. The pri-
mary causes of these diseases are smoking and alcohol and, thus, most
patients are smokers or newly quitters. Every head and neck cancer patient
treated with radiotherapy gets side effects. Currently, we do not know whether
smoking has an influence on the severity of these side effects, and this ques-
tion is what we seek an answer to in this thesis.
Materials: 795 patients with head and neck cancer who are registered in
the Danish Head and Neck Cancer Group’s database and treated with ra-
diotherapy in the period from 2000-2009 at Copenhagen University Hospital
(Rigshospitalet), are included in the study. The patients are divided into 3
groups: never smokers, ex-smokers and smokers. In logistic regressions, we
have looked at smoking and its effect on the side effects 6 and 12 months
after end of treatment, respectively. The 6 types of side effects considered
are: voice, fibrosis, dryness, dysphagia, atrophy and edema.
Results: A significant correlation between smoking at baseline and the side
effects dysphagia and edema after 12 months have been observed. We also
found a significant correlation between the amount of smoking per day and
the number of moderate to severe side effects. Also, quitting smoking during
treatment results in a significant reduction in the probability for experiencing
the side effects voice and edema.
Conclusions: The results are based on, as far as we know, the biggest data
material on smoking and late side effects of radiotherapy. We can conclude
that smoking cessation before or during treatment will have a positive effect
on the severity and amount of side effects.
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Purpose: To compare the probability of dysphagia (swallowing dysfunction)
with standard intensity modulated radiotherapy (st-IMRT), swallowing sparing
IMRT (sw-IMRT), standard scanned beam intensity-modulated proton therapy
(st-IMPT) and swallowing sparing IMPT (sw-IMPT).
Materials: Five patients with oropharyngeal cancer were treated with bilat-
eral irradiation on the primary tumor and the neck and were selected for this
planning comparative study. For each patient, st-IMRT, sw-IMRT, st-IMPT and
sw-IMPT simultaneous integrated boost treatment plans were created. In 35
similar fractions, a total dose of 70 Gy was delivered to the boost planning
target volume (PTV) and 54 Gy was delivered to the elective nodal PTV. The
st-IMRT and st-IMPT treatment plan optimization was performed to obtain ad-
equate target volume coverage, limited dose in critical structures such as the
spinal cord and sparing of the parotid glands as much as possible. These
primary objectives were similar for sw-IMRT and sw-IMPT, except that spe-
cific attempts were made to spare the organs at risk related to swallowing
dysfunction (SWOARs, Table 1). For all plans, normal tissue complication
probabilities of physician-rated and patient-rated dysphagia were calculated
with predictive models that were recently developed at our institute.
Results: All plans had adequate target volume coverage and the dose to crit-
ical organs was within accepted limits. The mean dose to the parotid glands
was similar for st-IMRT and sw-IMRT, and lowest with st-IMPT and sw-IMPT.
With sw-IMRT and sw-IMPT, the dose to the various SWOARs was reduced
when compared to st-IMRT and st-IMPT, respectively. In general, the lowest
dose to the SWOARs was obtained with sw-IMPT. The predicted mean prob-
ability of grade 2-4 physician rated dysphagia (RTOG) was 47%, 36%, 45%
and 31% with st-IMRT, sw-IMRT, st-IMPT and sw-IMPT, respectively. Patient
rated moderate to severe complaints with regard to the swallowing of solid
food, soft food, liquid food and aspiration with sw-IMRT and sw-IMPT were
similar (Table 1).
Conclusions: The predicted probability of different dysphagia-related end-
points with IMRT and IMPT was reduced by limiting the dose in the SWOARs.
The lowest probability of dysphagia was predicted with sw-IMPT.
